Amneal launches first generic equivalent to Lexapro in liquid form
Amneal Pharmaceuticals has launched escitalopram oxalate oral solution in 5 mg/5 mL strength, the first generic of antianxiety/antidepressant Lexapro (Forest) in liquid form on the market
Amneal Pharmaceuticals has launched escitalopram oxalate oral solution in 5 mg/5 mL strength, the first generic of antianxiety/antidepressant Lexapro (Forest) in liquid form on the market.
Annual US sales of Lexapro Oral Solution are $7.3 million according to December 2011 IMS Health market data.
Escitalopram oxalate oral solution is available in an 8-fl. oz./240-mL bottle that does not require refrigeration. The clear, pale yellow liquid comes in peppermint flavor.
“As a first-to-market generic, escitalopram oxalate oral solution provides a significantly less-expensive alternative to the brand pharmaceutical, especially for patients in hospitals and managed care who cannot swallow oral solids,” Chirag Patel, Amneal’s president, told Formulary. “This product helps reduce expenses for the patient, reduces the overall cost of healthcare, and improves pharmacy margins. Everyone gains in that equation.”
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
